Omar Alhalabi, MD

Peer-Reviewed Articles

1. Jindal T, Jiang C, Alhalabi O, Nizam A, Nguyen C, Talukder R, Bakaloudi D, Davidsohn M, Freeman D, Glover M, Khaki AR, Evans S, Lemke E, Bose R, Sim W, Pywell C, Basu A, Kilari D, Barata PC, Bilen MA, Zakharia Y, Milowsky MI, Shah SA, Bellmunt J, Grivas P, Emamekhoo H, Davis NB, Gupta S, Hoimes C, Campbell MT, Alva A, Koshkin VS. Genomic Biomarkers Associated with Enfortumab Vedotin Outcomes for Patients with Advanced Urothelial Carcinoma: Analysis of UNITE Study Data. Eur Urol Oncol None(None):None, 2024. PMID: 39709257.
2. Alhalabi O. 516 Immune checkpoint inhibitors in advanced urachal and non-urachal adenocarcinomas of the urinary tract: the MD Anderson Cancer Center experience. BMJ Specialist Journals 12(SUPPL 2):None, 2024. PMID: None.
3. Carriere P, Alhalabi O, Gao J, Mohamad O, Campbell MT, Shah A, Goswami S, Bree K, Lee B, Navai N, Mok H, Mayo L, Guo C, Nguyen Q, McGuire S, Park R, Shah S, Hoffman K, Frank S, Tang C, Choi S, Kamat A, Hassanzadeh C. Bladder-preserving radiation therapy for patients with locally advanced and node-positive bladder cancer. Clin Transl Radiat Oncol 49(None):100866, 2024. PMID: 39403573.
4. Myers AA, Fang AM, Moussa MJ, Hwang H, Wilson NR, Campbell MT, Msaouel P, Lee BH, Guo CC, Zhang M, Zhao J, Siefker-Radtke AO, Kamat AM, Alhalabi O. Impact of systemic therapy on clinical T1 small-cell neuroendocrine carcinoma of the bladder. ESMO Open 9(11):103964, 2024. PMID: 39471563.
5. Matin, S, Adibi, M, Shah, AY, Alhalabi, O, Corn, P, Guo, C, Amirtharaj, R, Xiao, L, Lange, S, Duose, D, Wang, S, Pal, S, Campbell, M. Phase 1b Trial Evaluating Tolerability and Activity of Targeted Fibroblast Growth Factor Receptor Inhibition in Localized Upper Tract Urothelial Carcinoma. Journal of Urology 211(6):784-792, 2024. PMID: 38573872.
6. Zheng L, Chen H, Zhao J, Roy-Chowdhuri S, Kamat AM, Alhalabi O, Gao J, Siefker-Radtke A, Hansel DE, Czerniak B, Guo CC. Plasmacytoid urothelial carcinoma of the urinary bladder-A clinicopathological and molecular analysis of 52 cases. Hum Pathol 148:1-6, 2024. PMID: 38679207.
7. Hahn AW, Surasi DS, Viscuse PV, Bathala TK, Wiele AJ, Campbell MT, Zurita AJ, Shah AY, Jonasch E, Gao J, Goswami S, Alhalabi O, Rao P, Sircar K, Tannir NM, Msaouel P. Treatment Outcomes in Patients With Metastatic Renal Cell Carcinoma With Sarcomatoid and/or Rhabdoid Dedifferentiation After Progression on Immune Checkpoint Therapy. Oncologist 29(5):392-399, 2024. e-Pub 2023. PMID: 38035767.
8. Cho WC, Saade R, Nagarajan P, Aung PP, Milton DR, Marques-Piubelli ML, Hudgens C, Ledesma D, Nelson K, Ivan D, Zhang M, Torres-Cabala CA, Campbell M, Alhalabi O, Prieto VG, Wistuba II, Esmaeli B, Curry JL. Nectin-4 expression in a subset of cutaneous adnexal carcinomas: A potential target for therapy with enfortumab vedotin. J Cutan Pathol 51(5):360-367, 2024. e-Pub 2024. PMID: 38200650.
9. Sood A, Rudzinski JK, Labbate CV, Hensley PJ, Bree KK, Guo CC, Alhalabi O, Campbell MT, Siefker-Radtke AO, Navai N, Dinney CPN, Gao J, Kamat AM. Long-Term Oncological Outcomes in Patients Diagnosed with Non-Metastatic Plasmacytoid Variant of Bladder Cancer: A 20-Year University of Texas MD Anderson Cancer Center Experience. J Urol 211(2):101097JU0000000000003778, 2024. e-Pub 2023. PMID: 37922370.
10. Alhalabi O, Wilson N, Xiao L, Lin Y, Khandelwal J, Moussa MJ, Msaouel P, Navai N, Gao J, Kamat AM, Pilie P, Shah AY, Goswami S, Matin S, Kovitz C, Holla V, Guo C, Czerniak B, Logothetis C, Corn PG, Dinney CPN, Campbell MT, Hansel DE, Tannir NM, Siefker-Radtke AO. Comparative Effectiveness Analysis of Treatment Strategies for Surgically Resectable Neuroendocrine Carcinoma of the Urinary Tract. Eur Urol Oncol 6(6):611-620, 2023. e-Pub 2023. PMID: 37833193.
11. Lu X, Tawanaie Pour Sedehi N, Su X, Yan F, Alhalabi O, Tannir NM, Malouf GG. Racial Disparities in MiT Family Translocation Renal Cell Carcinoma. Oncologist 28(11):1009-1013, 2023. e-Pub 2023. PMID: 37315151.
12. Siefker-Radtke AO, Cauley D, Alhalabi O. Combinations, Sequencing, and the Contribution of Components: New Frontline Standards for Metastatic Urothelial Carcinoma. J Clin Oncol 41(25):JCO2300987, 2023. e-Pub 2023. PMID: 37490639.
13. Saji A, Chopra M, Jacob J, Altan M, Alhalabi O, Shah AY, Qiao W, Wang Y, Thomas A. Implementing an immunotherapy toxicity (IOTOX) GI service improves outcomes in patients with immune-mediated diarrhea and colitis. J Cancer Res Clin Oncol 149(9):1-12, 2023. e-Pub 2022. PMID: 36585982.
14. Mathew A, Shatila M, Lai Z, Tan D, Oliva ICG, Wang J, Alhalabi O, Zhang HC, Thomas A, Wang Y. Characteristics of appendicitis after immune checkpoint inhibitor therapy among cancer patients. J Cancer Res Clin Oncol 149(8):4591-4599, 2023. e-Pub 2022. PMID: 36163559.
15. Liu C, Amin R, Shatila M, Short N, Altan M, Shah A, Alhalabi O, Okhuysen P, Thomas AS, Wang Y. Clinical characteristics and outcomes of tyrosine kinase inhibitor-related lower GI adverse effects. J Cancer Res Clin Oncol 149(7):3965-3976, 2023. e-Pub 2022. PMID: 36030431.
16. Alhalabi O, Thouvenin J, Négrier S, Vano YA, Campedel L, Hasanov E, Bakouny Z, Hahn AW, Bilen MA, Msaouel P, Choueiri TK, Viswanathan SR, Sircar K, Albiges L, Malouf GG, Tannir NM. Immune Checkpoint Therapy Combinations in Adult Advanced MiT Family Translocation Renal Cell Carcinomas. Oncologist 28(5):433-439, 2023. e-Pub 2023. PMID: 36640141.
17. Tan WS, Tan MY, Alhalabi O, Campbell MT, Kamat AM, Gao J. Evolving systemic management of urothelial cancers. Curr Opin Oncol 35(3):186-199, 2023. e-Pub 2023. PMID: 36966497.
18. Alhalabi O, Zhu Y, Hamza A, Qiao W, Lin Y, Wang RM, Shah AY, Campbell MT, Holla V, Kamat A, Wang WL, Wang J, Chen J, Meng J, Zhang M, Bondaruk J, Titus M, Genovese G, Czerniak BA, Shaw KR, Meric-Bernstam F, Guo CC, Logothetis CJ, Siefker-Radtke A, Msaouel P, Wang L, Liu J, Gao J. Integrative Clinical and Genomic Characterization of MTAP-deficient Metastatic Urothelial Cancer. Eur Urol Oncol 6(2):228-232, 2023. e-Pub 2021. PMID: 34789422.
19. Leo J, Dondossola E, Basham KJ, Wilson NR, Alhalabi O, Gao J, Kurnit KC, White MG, McQuade JL, Westin SN, Wellberg EA, Frigo DE. Stranger Things: New Roles and Opportunities for Androgen Receptor in Oncology Beyond Prostate Cancer. Endocrinology 164(6), 2023. e-Pub 2023. PMID: 37154098.
20. Thouvenin J, Alhalabi O, Carlo M, Carril-Ajuria L, Hirsch L, Martinez-Chanza N, Négrier S, Campedel L, Martini D, Borchiellini D, Chahoud J, Lodi M, Barthélémy P, Hasanov E, Hahn AW, Gil T, Viswanathan SR, Bakouny Z, Msaouel P, Asim Bilen M, Choueiri TK, Albiges L, Tannir NM, Malouf GG. Efficacy of Cabozantinib in Metastatic MiT Family Translocation Renal Cell Carcinomas. Oncologist 27(12):1041-1047, 2022. PMID: 35979929.
21. Alhalabi O, Chen J, Zhang Y, Lu Y, Wang Q, Ramachandran S, Tidwell RS, Han G, Yan X, Meng J, Wang R, Hoang AG, Wang WL, Song J, Lopez L, Andreev-Drakhlin A, Siefker-Radtke A, Zhang X, Benedict WF, Shah AY, Wang J, Msaouel P, Zhang M, Guo CC, Czerniak B, Behrens C, Soto L, Papadimitrakopoulou V, Lewis J, Rinsurongkawong W, Rinsurongkawong V, Lee J, Roth J, Swisher S, Wistuba I, Heymach J, Wang J, Campbell MT, Efstathiou E, Titus M, Logothetis CJ, Ho TH, Zhang J, Wang L, Gao J. MTAP deficiency creates an exploitable target for antifolate therapy in 9p21-loss cancers. Nat Commun Paper #NCOMMS-20-37775B(1):1797, 2022. e-Pub 2022. PMID: 35379845.
22. Alhalabi O, Hahn AW, Msaouel P, Meric-Bernstam F, Wilson N, Naing A, Piha-Paul S, Janku F, Pant S, Yap TA, Hong DS, Fu S, Karp D, Beltran K, Campbell E, Le H, Campbell MT, Shah A, Tannir NM, Siefker-Radtke A, Gao J, Roszik J, Subbiah V. Validation of Prognostic Scores in Patients with Metastatic Urothelial Cancer Enrolling in Phase I Targeted Therapy or Next Generation Immunotherapy Trials. Clin Genitourin Cancer 20(1):e16-e24, 2022. e-Pub 2021. PMID: 34362693.
23. Alhalabi O, Altameemi L, Campbell MT, Meric-Bernstam F. Recent Advances in the Development of Antibody-Drug Conjugates in Urothelial Cancer. Cancer J 28(6):417-422, 2022. PMID: 36383903.
24. Hensley PJ, Bree KK, Campbell MT, Alhalabi O, Kokorovic A, Miest T, Nogueras-Gonzalez GM, Gao J, Siefker-Radtke AO, Guo CC, Navai N, Dinney CP, Kamat AM. Progression of Disease after BCG Therapy: Refining Patient Selection for Neoadjuvant Chemotherapy before Radical Cystectomy. J Urol 206(5):101097JU0000000000001943, 2021. e-Pub 2021. PMID: 34184926.
25. Hensley PJ, Bree KK, Campbell MT, Alhalabi O, Kokorovic A, Miest T, Nogueras-Gonzalez GM, Gao J, Siefker-Radtke AO, Guo CC, Navai N, Dinney CP, Kamat AM. Reply by Authors. J Urol 206(5):101097JU000000000000194302, 2021. e-Pub 2021. PMID: 34372685.
26. Alhalabi O, Campbell MT, Xiao L, Adriazola AC, Wilson NR, Siefker-Radtke AO, Corn PG, Zurita A, Jonasch E, Gao J, Abidi M, Kamat AM, Navai N, Pisters LL, Dinney C, Matin SF, Shah AY. Multimodal kidney-preserving approach in localised and locally advanced high-risk upper tract urothelial carcinoma. BJUI Compass 3(1):37-44, 2021. e-Pub 2022. PMID: 35475152.
27. Benkhadra R, Nayfeh T, Patibandla SK, Peterson C, Prokop L, Alhalabi O, Murad MH, Mao SS. Systematic Review and Meta-Analysis of Cisplatin Based Neoadjuvant Chemotherapy in Muscle Invasive Bladder Cancer. Bladder Cancer, 2021. PMID: None.
28. Han G, Yang G, Hao D, Lu Y, Thein K, Simpson BS, Chen J, Sun R, Alhalabi O, Wang R, Dang M, Dai E, Zhang S, Nie F, Zhao S, Guo C, Hamza A, Czerniak B, Cheng C, Siefker-Radtke A, Bhat K, Futreal A, Peng G, Wargo J, Peng W, Kadara H, Ajani J, Swanton C, Litchfield K, Ahnert JR, Gao J, Wang L. 9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy. Nat Commun 12(1):5606, 2021. e-Pub 2021. PMID: 34556668.
29. Elmehrath AO, Afifi AM, Al-Husseini MJ, Saad AM, Wilson N, Shohdy KS, Pilie P, Sonbol MB, (Corresponding author) AO. Causes of Death Among Patients With Metastatic Prostate Cancer in the US From 2000 to 2016. JAMA Netw Open 4(8):e2119568, 2021. e-Pub 2021. PMID: 34351403.
30. Alhalabi O, Hasanov E, Wilson NR, Araujo J, Wang J, Campbell MT, Goswami S, Shah AY, Gao J, Msaouel P, Tannir NM. Outcomes of patients with intermediate-risk or poor-risk metastatic renal cell carcinoma who received their first cycle of nivolumab and ipilimumab in the hospital because of symptomatic disease: The MD Anderson Cancer Center experience. Int J Cancer 149(2):387-393, 2021. e-Pub 2021. PMID: 33739450.
31. Andreev-Drakhlin AY, Egoryan G, Shah AY, Msaouel P, Alhalabi O, Gao J. The Evolving Treatment Landscape of Advanced Urothelial Carcinoma. Curr Opin Oncol 33(3):221-230, 2021. PMID: 33818541.
32. Alhalabi O, Soomro Z, Sun R, Hasanov E, Albittar A, Tripathy D, Valero V, Ibrahim NK. Outcomes of changing systemic therapy in patients with relapsed breast cancer and 1 to 3 brain metastases. NPJ Breast Cancer 7(1):28, 2021. e-Pub 2021. PMID: 33742001.
33. Alhalabi O, Hahn AW, Msaouel P, Andreev-Drakhlin AY, Meric-Bernstam F, Naing A, Piha-Paul S, Filip J, Pant S, Yap TA, Hong DS, Fu S, Karp D, Campbell E, Le H, Campbell MT, Shah AY, Tannir NM, Siefker-Radtke AO, Gao J, Roszik J, Subbiah V. Molecular profiling of metastatic bladder cancer early-phase clinical trial participants predicts patient outcomes. Mol Cancer Res 19(3):395-402, 2021. e-Pub 2020. PMID: 33323389.
34. Alhalabi, O, Hasanov, E, Wilson, N, Araujo, J, Wang, J, Campbell, Goswami M, S, Shah, AY, Gao, J, Msaouel, P, Tannir, N. Outcomes of patients with intermediate- or poor-risk metastatic renal cell carcinoma who received their first cycle of nivolumab and ipilimumab in the hospital because of symptomatic disease: The MD Anderson Cancer Center experience. International Journal of Cancer, 2021. PMID: None.
35. Alhalabi O, Msaouel P. Truncating CDKN1A mutations: an insight into the biology of urinary tract carcinomas?. Am J Cancer Res 11(12):6214-6217, 2021. e-Pub 2021. PMID: 35018253.
36. Gao J, Navai N, Alhalabi O, Siefker-Radtke A, Campbell MT, Tidwell RS, Guo CC, Kamat AM, Matin SF, Araujo JC, Shah AY, Msaouel P, Corn P, Wang J, Papadopoulos JN, Yadav SS, Blando JM, Duan F, Basu S, Liu W, Shen Y, Zhang Y, Macaluso MD, Wang Y, Chen J, Zhang J, Futreal A, Dinney C, Allison JP, Goswami S, Sharma P. Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma. Nat Med 26(12):1845-1851, 2020. e-Pub 2020. PMID: 33046869.
37. AW* H, O* A, Msaouel P, Meric-Bernstam F, Naing A, Jonasch E, Piha-Paul S, Hong D, Pant S, Yap T, Campbell E, Le H, Tannir NM, Roszik J, Subbiah V. Validation of prognostic scoring systems for patients with metastatic renal cell carcinoma enrolled in phase I clinical trials. ESMO Open 5(6), 2020. PMID: 33229506.
38. Alahdab F, Zuhri Yafi R, Chaar A, Alrstom A, Alzuabi M, Alhalabi O, Hasan S, Mallak M, Jazayerli ML, Haydour Q, Alkhouli M, Alfarkh W, Murad MH. Aspirin dosage for the prevention of graft occlusion in people undergoing coronary surgery: A systematic review and meta-analysis. Avicenna J Med 10(4):198-207, 2020. PMID: 33437691.
39. Alhalabi O, Subbiah V. Managing Cancer Care during the COVID-19 Pandemic and Beyond. Trends Cancer 6(7):533-535, 2020. e-Pub 2020. PMID: 32386875.
40. Alhalabi O, Iyer S, Subbiah V. Testing for COVID-19 in patients with cancer. EClinicalMedicine 23:100374, 2020. e-Pub 2020. PMID: 32368727.
41. Alhalabi O, Campbell M, Shah A, Siefker-Radtke A, Gao J. Emerging treatments in advanced urothelial cancer. Curr Opin Oncol 32(3):232-239, 2020. PMID: 32209822.
42. Parkes A, Warneke CL, Clifton K, Al-Awadhi A, Oke O, Pestana RC, Alhalabi O, Litton JK, Hortobagyi GN. Prognostic Factors in Patients with Metastatic Breast Cancer with Bone-Only Metastases. Oncologist 23(11):1282-1288, 2018. e-Pub 2018. PMID: 30120166.
43. Yadav S, Ladkany R, Yadav D, Alhalabi O, Khaddam S, Isaac D, Cardenas PY, Zakalik D. Impact of BRCA Mutation Status on Survival of Women With Triple-negative Breast Cancer. Clin Breast Cancer 18(5):e1229-e1235, 2018. e-Pub 2017. PMID: 29402697.
44. Stavrou EX, Fang C, Bane KL, Long AT, Naudin C, Kucukal E, Gandhi A, Brett-Morris A, Mumaw MM, Izadmehr S, Merkulova A, Reynolds CC, Alhalabi O, Nayak L, Yu WM, Qu CK, Meyerson HJ, Dubyak GR, Gurkan UA, Nieman MT, Sen Gupta A, Renné T, Schmaier AH. Factor XII and uPAR upregulate neutrophil functions to influence wound healing. J Clin Invest 128(3):944-959, 2018. e-Pub 2018. PMID: 29376892.
45. Gjeorgjievski M, Alhalabi O, Kazanji N, Desai T. Clostridium septicum arthritis and aortitis in a patient with underlying colon cancer. QJM 109(7):481-2, 2016. e-Pub 2016. PMID: 26803153.
46. HR* G, A* M, O* A, Stavrou EX, Veigl ML, Barnholtz-Sloan JS, Schmaier AH. A Cross-sectional Study of KLKB1 and PRCP Polymorphisms in Patient Samples with Cardiovascular Disease. Front Med (Lausanne) 3:17, 2016. e-Pub 2016. PMID: 27200353.
47. Stavrou EX, Fang C, Merkulova A, Alhalabi O, Grobe N, Antoniak S, Mackman N, Schmaier AH. Reduced thrombosis in Klkb1-/- mice is mediated by increased Mas receptor, prostacyclin, Sirt1, and KLF4 and decreased tissue factor. Blood 125(4):710-9, 2015. e-Pub 2014. PMID: 25339356.

Invited Articles

1. Alhalabi O. 1972P Pre-treatment (Tx) risk factors for enfortumab vedotin-induced peripheral neuropathy (EVIPN) in patients (pts) with advanced urothelial carcinoma (aUC): Analysis of UNITE. None 35(Suppl 2):S1142, 2024. PMID: None.

Other Articles

1. Crupi E, Costa de Padua T, Marandino L, Fallara G, Pederzoli F, Cimadamore A, Goetz EC, Cigliola A, Patane DA, Mercinelli C, Tateo V, Salonia A, Briganti A, Montorsi F, Meeks JJ, Spiess PE, Alhalabi O, Gao J, Kamat AM, Grivas P, Necchi A, Raggi D Nectin-4 Positivity in Genitourinary Malignancies: A Systematic Review. JCO Precis Oncol 8(None):e2400470, 2024. PMID: 39626158.
2. Alhalabi O 1988P Enfortumab vedotin (EV) + pembrolizumab (P) outcomes outside clinical trials and biomarkers of benefit in patients (pts) with advanced urothelial carcinoma: Analysis of the UNITE study. None 35(None):S1149-S1150, 2024. PMID: None.
3. Moussa MJ, Khandelwal J, Wilson NR, Naik SA, Subbiah V, Campbell MT, Msaouel P, Singh P, Alhalabi O Durable Objective Response to Lurbinectedin in Small Cell Bladder Cancer with TP53 Mutation: A Molecular-Directed Strategy. Curr Oncol 31(6):3342-3349, 2024. PMID: 38920737.
4. Alhalabi O Prognostic factors of relapse in surgically resected small cell neuroendocrine carcinomas of the urothelial tract (SCNEC-URO). None 42(16_suppl):4605-4605, 2024. PMID: None.
5. Moussa, MJ, Campbell, M, Alhalabi, O Revisiting Treatment of Metastatic Urothelial Cancer. Biomedicines 12(3), 2024. PMID: 38540132.
6. Alhalabi O, Groisberg R, Zinner R, Hahn AW, Naing A, Zhang S, Tsimberidou AM, Rodon J, Fu S, Yap TA, Hong DS, Sun M, Jiang Y, Pant S, Shah AY, Zurita A, Tannir NM, Vikram R, Roszik J, Meric-Bernstam F, Subbiah V Phase I study of sapanisertib with carboplatin and paclitaxel in mTOR pathway altered solid malignancies. NPJ Precis Oncol 7(1):37, 2023. PMID: 37072571.
7. Kovalenko, I, Lynn Ng, W, Geng, Y, Wang, Y, Msaouel, P, Bhatia, S, Grivas, PD, Benkhadra, R, Alhalabi, O Adverse events of immune checkpoint therapy alone versus when combined with vascular endothelial growth factor inhibitors. Frontiers in Oncology 13, 2023. PMID: 38239644.
8. Machado AP, Ratliff H, Abdelwahab A, Vohra MH, Kuang A, Shatila M, Khan MA, Shafi MA, Thomas AS, Philpott J, Alhalabi O, Wang Y The Safety of Immunosuppressants Used in the Treatment of Immune-Related Adverse Events due to Immune Checkpoint Inhibitors: a Systematic Review. J Cancer 14(16):2956-2963, 2023. PMID: 37859810.
9. Benkhadra, R, Nayfeh, T, Patibandla, SK, Peterson, C, Prokop, LJ, Alhalabi, O, Murad, MH, Mao, SS Systematic Review and Meta-Analysis of Cisplatin Based Neoadjuvant Chemotherapy in Muscle Invasive Bladder Cancer. Bladder Cancer 8(1):5-17, 2022. PMID: 38994516.
10. Thouvenin J, Martínez Chanzá N, Alhalabi O, Lang H, Tannir NM, Barthélémy P, Malouf GG Efficacy of Immune Checkpoint Inhibitors in Upper Tract Urothelial Carcinomas: Current Knowledge and Future Directions. Cancers (Basel) 13(17), 2021. PMID: 34503152.
11. Ravindranathan D, Alhalabi O, Rafei H, Shah AY, Bilen MA Landscape of Immunotherapy in Genitourinary Malignancies. Adv Exp Med Biol 1342:143-192, 2021. PMID: 34972965.
12. Alhalabi O, Rafei H, Bilen MA, Shah AY Current Landscape of Immunotherapy in Genitourinary Malignancies. Adv Exp Med Biol 1244:107-147, 2020. PMID: 32301013.
13. Albittar AA, Alhalabi O, Glitza Oliva IC Immunotherapy for Melanoma. Adv Exp Med Biol 1244:51-68, 2020. PMID: 32301010.
14. Alhalabi O, Karam JA, Tannir NM Evolving role of cytoreductive nephrectomy in metastatic renal cell carcinoma of variant histology. Curr Opin Urol 29(5):521-525, 2019. PMID: 31305271.
15. Alhalabi O, Rafei H, Shah A, Siefker-Radtke A, Campbell M, Gao J Targeting advanced urothelial carcinoma-developing strategies. Curr Opin Oncol 31(3):207-215, 2019. PMID: 30844889.
16. Alhalabi O, Shah AY, Lemke EA, Gao J Current and Future Landscape of Immune Checkpoint Inhibitors in Urothelial Cancer. Oncology (Williston Park) 33(1):11-8, 2019. PMID: 30731013.
17. Wei C, Wei C, Alhalabi O, Chen L T-cell/histiocyte-rich large B-cell lymphoma in a child: A case report and review of literature. World J Clin Cases 6(6):121-126, 2018. PMID: 29988902.
18. Tagami T, Alhalabi O, Ward N, Huang J Paraneoplastic Dermatosis in a Patient with Anaplastic Large-Cell Lymphoma: Case Report and Literature Review. Dermatopathology (Basel) 3(2):39-43, 2016. PMID: 27504444.

Abstracts

1. Alhalabi O. 1186 Early detection of immune-related adverse events to reduce hospitalization rates. JITC 12(Suppl 2):None, 2024. PMID: None.
2. Alhalabi O. 1187 Core needle biopsy for diagnosis of immune-mediated myositis. JITC 12(Suppl 2):None, 2024. PMID: None.
3. Alhalabi O. Severe Genitourinary Events Following Definitive Radiation Therapy for Patients with Locally Advanced and Metastatic Bladder Cancer: A Single Institution Experience. None 120(2):e517-e518, 2024. PMID: None.
4. Alhalabi O. OCTS-06 A PHASE II STUDY OF NIVOLUMAB WITH IPILIMUMAB AND CABOZANTINIB IN PATIENTS WITH UNTREATED RENAL CELL CARCINOMA BRAIN METASTASES. None 6(Supplement_1):i27-i28, 2024. PMID: None.
5. Alhalabi O. IK-175, an oral AHR inhibitor, as monotherapy and in combination with nivolumab in patients with urothelial carcinoma resistant/refractory to PD-1/L1 inhibitors. None 42(16_suppl):2599-2599, 2024. PMID: None.
6. Alhalabi O. Gemcitabine/paclitaxel/adriamycin (GTA) as a nephron-sparing regimen in urothelial carcinoma: The MD Anderson Cancer Center (MDACC) experience. None 42(16_suppl):e16576-e16576, 2024. PMID: None.
7. Wang J, Campbell MT, Shah AY, Goswami S, Masaouel P, Alhalabi O, Hahn AW, Kovitz CA, Jana BR, Araujo JC. A phase II study of nivolumab with ipilimumab and cabozantinib in patients with untreated renal cell carcinoma brain metastases. American Society of Clinical Oncology, 2023. PMID: None.
8. Koshkin VS, Henderson N, Kilari D, Jindal T, Alhalabi O, Freeman Dm Basu A, Barata PC, Bilen MA, Zakharia Y. Enfortumab vedotin (EV) outcomes with and without immediate prior immune checkpoint inhibitor (ICI) in patients (tpts) with advanced urothelial carcinoma (aUC). American Society of Clinical Oncology, 2023. PMID: None.
9. Jindal T, Kilari D, Alhalabi O, Nizam A, Khaki AR, Basu A, Barata PC, Bilen M, Shah S, Zakharia Y. Biomarkers of response to enfortumab vedotin (EV) in patients (pts) with advanced urothelial carcinoma (aUC): Analysis of the UNITE study. American Society of Clinical Oncology, 2023. PMID: None.
10. Alhalabi O, Wilson N, Ajufo H, Lehner M, Hasanov E, Campbell MT, Yogesh Shah A, Wang J, Jonasch E, John A, Wang J, Gao J, Goswami S, Msaouel P, Tannir N. Safety and differential clinical activity of nivolumab plus ipilimumab (nivo-ipi) in patients (pts) with non-clear cell renal cell carcinoma (nccRCC). Journal of Clinical Oncology DOI: 10.1200/JCO.2022.40.6_suppl.356 Journal of Clinical Oncology 40, no. 6_suppl (February 20, 2022) 356-356, 2022. PMID: None.
11. Alhalabi O, Thouvenin J, Negrier S, Vano Y, Campedel L, Hasanov E, Bakouny Z, Hahn A, Bilen M, Choueiri T, Viswanathan S, Sircar K, Albiges L, Malouf G, Tannir N. Immuno-oncology (IO) combinations +/- VEGF targeted therapy (VEGF TT) in patients (pts) with advanced mit family translocation renal cell carcinomas (tRCC): Results from an international multicenter study. Journal of Clinical Oncology DOI: 10.1200/JCO.2022.40.6_suppl.343 Journal of Clinical Oncology 40, no. 6_suppl (February 20, 2022) 343-343, 2022. PMID: None.
12. Hahn AW, Viscuse P, Surasi D, Bathala T, Wiele A, Starbuck M, Campbell MT, Yogesh Shah A, Jonasch E, Gao JJ, Alhalabi O, Sircar K, Tannir N, Msaouel P. Treatment outcomes in patients (pts) with metastatic renal cell carcinoma (mRCC) with sarcomatoid and/or rhabdoid (S/R) features after progressive disease (PD) on immune checkpoint therapy (ICT): The MD Anderson Cancer Center experience. Journal of Clinical Oncology DOI: 10.1200/JCO.2022.40.6_suppl.351 Journal of Clinical Oncology 40, no. 6_suppl (February 20, 2022) 351-351, 2022. PMID: None.
13. Alhalabi O, Wilson N, Xiao L, Navai N, Kamat A, Yogesh Shah A, Araujo J, Wang J, Goswami S, Gao JJ, Wang J, Guo C, Czerniak B, Corn P, Logothetis C, Dinney C, Campbell MT, Tannir N, Siefker-Radtke A. Factors associated with improved outcomes in surgically resectable small cell urothelial cancer (SCUC). Journal of Clinical Oncology DOI: 10.1200/JCO.2022.40.6_suppl.495 Journal of Clinical Oncology 40, no. 6_suppl (February 20, 2022) 495-495, 2022. PMID: None.
14. Saji A, Chopra M, Jacob J, Altan M, Alhalabi O, Shah AY, Qiao W, Wang Y, Thomas A. Implementing an Immunotherapy Toxicity (IOTOX) GI Service Improves Outcomes in Patients with Immune Mediated Diarrhea and Colitis. DOI: 10.21203/rs.3.rs-2216829/v, 2022. PMID: None.
15. Reddy, N K, Roszik, J, Norris, D C, Groisberg, R, Coleman, N, Alhalabi, O, Subbiah, V. Dosing, drug reduction, drug interruption, and drug discontinuation rates among U.S. FDA approved tyrosine kinase inhibitors. Journal of Clinical Oncology, 39(15_suppl), 3112-3112. doi:10.1200/JCO.2021.39.15_suppl.3112, 2021. PMID: None.
16. Alhalabi, O, Naing, A, Groisberg, R, Hahn, A, Zhang, S, Berkey, SC, Subbiah, V. Phase I study of mTORC1-2 inhibitor sapanisertib (TAK-228) in combination with carboplatin plus paclitaxelin patients with advanced solid malignancies and mTOR pathway alterations. Cancer Research, 81(13 Supplement), CT109. doi:10.1158/1538-7445.AM2021-CT109 39(6):274, 2021. PMID: None.
17. Wilson N, Alhalabi O, Hasanov E, et al. 241 Immune checkpoint blockade (ICB) in brain metastases (BM) from advanced small cell urothelial cancer (aSCUC). Journal for ImmunoTherapy of Cancer 2021;9:doi: 10.1136/jitc-2021-SITC2021.241, 2021. PMID: None.
18. Andreev-Drakhlin, A, Shah, A Y, Adriazola, A C, Shaw, L, Lopez, L, James, M, Matin, S F, Alhalabi, O, Gao, J, Siefker-Radtke, A O, Goswami, S, Xiao, L, Venkatesan, A M, Campbell A, M T. Efficacy of immune checkpoint blockade in patients with advanced upper tract urothelial cancer and mismatch repair deficiency or microsatellite instability (MSI). Journal of Clinical Oncology 39, 487-487, 2021. PMID: None.
19. Thouvenin, J, Alhalabi, O, Hirsch, L, Hasanov, E, Barthelemy, P, Martini, D J, Malouf, G G. Efficacy of cabozantinib in advanced MiT family translocation renal cell carcinomas (TRCC). Journal of Clinical Oncology 39(6_suppl), 274-274. doi:10.1200/JCO.2021.39.6_suppl.274 81(13), 2021. PMID: None.
20. Benkhadra, R, Nayfeh, T, Patibandla, N S K, Peterson, C, Prokop, L, Alhalabi, O, Murad MH, Mao. Methotrexate, vinblastine, adriamycin, and cisplatin (MVAC) versus gemcitabine, and cisplatin (GC) as neoadjuvant chemotherapy in muscle-invasive bladder cancer, a systematic review and meta-analysis. Journal of Clinical Oncology, 39(15_suppl), e16522-e16522. doi:10.1200/JCO.2021.39.15_suppl.e16522, 2021. PMID: None.
21. Alhalabi, O, Wilson, N, Navai, N, Campbell, M T, Shah, A Y, Gao, J, Siefker-Radtke, A O. Survival outcomes in patients receiving immune checkpoint inhibitor (ICI) for metastatic small cell urothelial cancer (SCUC). Journal of Clinical Oncology, 39(15_suppl), 4543-4543. doi:10.1200/JCO.2021.39.15_suppl.4543, 2021. PMID: None.
22. Alhalabi O, Hasanov E, Araujo J, Wang J, Campbell MT, Goswami S, Shah AY, Gao J, Msaouel P, Tannir N. 441 Outcomes of patients with metastatic renal cell carcinoma with intermediate- or poor-risk symptomatic disease who received their first cycle of nivolumab and ipilimumab while being hospitalized. Journal for ImmunoTherapy of Cancer (JITC), 2020. PMID: None.
23. Hahn, AW, Alhalabi, al O. Phase I clinical trials as a therapeutic option for patients with metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology 38, 5073-5073, 2020. PMID: None.
24. Alhalabi, O, et al. Outcomes and the impact of genomic characteristics on patients with metastatic urothelial carcinoma enrolled in early phase trials. Journal of Clinical Oncology 38, 5029-5029, 2020. PMID: None.
25. Alhalabi O, Campbell MT, Slack-Tidwell R, Siefker-Radtke AO, Shah AY, Efstathiou E, et al. A phase II trial to evaluate pemetrexed clinical responses in relation to tumor methylthioadenosine phosphorylase (MTAP) gene status in patients with previously treated metastatic urothelial carcinoma. Journal of Clinical Oncology. 2019;37(7_suppl):385-, 2019. PMID: None.
26. Alhalabi O, Chen J, Campbell MT, Slack Tidwell R, Han G, W-L W, et al. Correlation of methylthioadenosine phosphorylase (MTAP) loss with response to anti-folate therapy in urothelial bladder carcinoma (UBC). Journal of Clinical Oncology. 2019;37(15_suppl):4521-, 2019. PMID: None.
27. Alhalabi O, Yadav S, Jaiyesimi IA. Prescribing patterns of rasburicase and glucose-6-phosphate-dehydrogenase (G6PD) testing in a large community health system. Journal of Clinical Oncology. 2016;34(15_suppl):e18206-e, 2016. PMID: None.

Book Chapters

1. Alhalabi, O, Gao, J. Medical treatment with targeted therapy for metastatic urothelial bladder carcinoma, 199-209, 2021.
2. Ravindranathan, D, Alhalabi, O, Rafei, H, Shah, AY, Bilen, MA. Landscape of Immunotherapy in Genitourinary Malignancies, 143-192, 2021.
3. Alhalabi O, Ibrahim N. brain metastases in breast cancer. In: Holland-Frei Cancer Medicine. 10. None, 2021.
4. Alhalabi O, Abudayyeh A, Tannir N. Urologic Complications related to cancer and its treatment. In: Holland-Frei Cancer Medicine. 10th edition. None, 2021.
5. Alhalabi O, Rafei H, Bilen MA, Shah AY. None. In: Current Landscape of Immunotherapy in Genitourinary Malignancies. Immunotherapy 3rd edition. None. None, 2020.
6. Albittar A, Alhalabi O, Glitza I. None. In: Immunotherapy in Melanoma. Immunotherapy 3rd edition. None. None, 2020.
7. Alhalabi O, Gao J. None. In: Medical treatment with targeted therapy. Urinary Bladder Pathology 1st edition. None. None, 2020.